0M0F Stock Chart & Stats
$20.72
$1.20(7.21%)
At close: 4:00 PM EDT
$20.72
$1.20(7.21%)
Day’s Range― - ―
52-Week Range$11.48 - $29.47
Previous CloseN/A
Volume370.00
Average Volume (3M)702.00
Market Cap
$1.17B
Enterprise Value$1.32K
Total Cash (Recent Filing)$456.00M
Total Debt (Recent Filing)$739.25M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 04, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding69,578,705
10 Day Avg. Volume1,331
30 Day Avg. Volume702
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)9.53
Price to Sales (P/S)1.46
P/FCF Ratio-49.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.46Price Target Upside27.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$1.07B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueTandem’s installed-pump model creates an ongoing consumables revenue stream after the initial hardware sale. Required replenishment can improve customer lifetime value, support revenue visibility, and make successful pump adoption economically more durable over multiple quarters.
Improving Gross MarginsThe substantial gross-margin expansion, combined with reaffirmed 56%–57% guidance, indicates improving product economics rather than merely higher sales volume. Sustained margins would give Tandem more capacity to fund development, absorb operating costs, and move toward durable profitability.
Product And Technology PipelineAdvances across tubeless delivery, CGM interoperability, and the AdaNet algorithm strengthen Tandem’s product ecosystem and address important adoption drivers. These initiatives can broaden its addressable market, improve differentiation, and support future pump and supplies growth if execution continues.
Bears Say
High Financial LeverageA debt load far above the equity base leaves Tandem with a thin financial cushion while earnings remain negative. Elevated leverage can restrict investment flexibility, increase sensitivity to operating setbacks, and make the transition to sustainable profitability more consequential.
Inconsistent Cash GenerationAlthough operating cash flow has improved from the prior year, it remains small relative to losses and does not cover investment needs. Continued negative free cash flow means Tandem is not yet consistently self-funding, which can limit flexibility for product development and debt management.
Emerging Tubeless CompetitionNew patch and tubeless entrants could intensify competition in a high-growth segment where Tandem is pursuing Mobi. Competitive launches may raise the need for product investment and execution, while delays or weaker differentiation could pressure future adoption and recurring supplies growth.
Tandem Diabetes Care News
0M0F FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest share price was $11.48 and its highest was $29.47 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $1.17B.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Nov 04, 2026 which is in 44 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on Aug 06, 2026. The company reported -$0.307 earnings per share for the quarter, beating the consensus estimate of -$0.321 by $0.014.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.24.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 69,578,705 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.307 in its last earnings report, beating expectations of -$0.321. Following the earnings report the stock price went up 18.618%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in GB:0M0F
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.46 (27.72% Upside)
$26.46 (27.72% Upside)
Blogger Sentiment
Neutral
GB:0M0F Sentiment 50%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
0M0F Company Deck
0M0F Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational and financial progress: record quarterly sales and shipments, strong international growth, notable gross margin expansion, improving profitability, and clear product and pipeline milestones (Mobi tubeless filing, AdaNet IDE). Near-term challenges include infusion set supplier constraints, a temporary revenue headwind and margin variability from the pharmacy PayGo transition, distributor destocking, and the need to accelerate U.S. new-starts in H2 to meet guidance. On balance, the positives — sizable revenue and margin improvements, product launches, and early PayGo traction — outweigh the near-term operational headwinds, with the company reiterating full-year guidance.View all GB:0M0F earnings summaries0M0F Revenue Breakdown
74.21% U.S.
25.79% International
0M0F Stock 12 Month Forecast
Average Price Target
$26.46
▲(27.72% Upside)